FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4241169774> ?p ?o ?g. }

• W4241169774 endingPage "e11" @default.
• W4241169774 startingPage "e11" @default.
• W4241169774 abstract "We thank the authors for their detailed appraisal and positive comments about our study.1van Dijk E.H.C. Fauser S. Breukink M.B. et al.Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial.Ophthalmology. 2018; 125: 1547-1555Abstract Full Text Full Text PDF PubMed Scopus (133) Google Scholar In our study, we have included patients who had typical findings of chronic central serous chorioretinopathy (cCSC) on multimodal imaging. In this first PLACE trial report, we focused on the primary and secondary endpoints. Our study was designed primarily to assess a morphologic endpoint, namely, the complete resolution of subretinal fluid, which is a prerequisite for preserving and/or restoring function. With regard to the functional endpoints, microperimetry may be a more sensitive and earlier functional endpoint than best-corrected visual acuity, given that the recovery of best-corrected visual acuity can be delayed in cCSC after treatment.2Scholz P. Ersoy L. Boon C.J. Fauser S. Subthreshold micropulse laser (577 nm) treatment in chronic central serous chorioretinopathy.Ophthalmologica. 2015; 234: 189-194Crossref PubMed Scopus (50) Google Scholar Both the percentage of patients with complete resolution of subretinal fluid and the increase in retinal sensitivity on microperimetry was significantly higher in the patients who received half-dose photodynamic therapy compared with high-density subthreshold micropulse laser treatment. This was the case for both the first control visit and the final follow-up visit. We agree with the authors that photodynamic therapy currently represents the first-line choice for the treatment of cCSC patients.3Mehta P.H. Meyerle C. Sivaprasad S. et al.Preferred practice pattern in central serous chorioretinopathy.Br J Ophthalmol. 2017; 101: 587-590Crossref PubMed Scopus (28) Google Scholar However, this type of treatment may also be the first-line treatment of choice in patients with severe CSC. On this subject, we recently published an article, in which the outcome of treatment for patients with severe CSC proved to be roughly similar to findings that have been previously published for cCSC patients: 76% of treated eyes had no subretinal fluid on OCT at the final visit.4Mohabati D. van Rijssen T.J. van Dijk E.H. et al.Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy.Clin Ophthalmol. 2018; 12: 1061-1070Crossref PubMed Scopus (31) Google Scholar However, in upcoming studies we will further evaluate CSC subgroups and anatomic parameters, and we thank the authors for their valuable suggestions in this regard. Re: van Dijk et al: Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: The PLACE trial (Ophthalmology. 2018;125:1547-1555)OphthalmologyVol. 126Issue 1PreviewWe read with interest the article by van Dijk et al1 concerning the effects of half-dose photodynamic therapy (PDT) and high-density subthreshold micropulse laser for the treatment of patients with chronic central serous chorioretinopathy (cCSC). The authors concluded that half-dose PDT is superior to high-density subthreshold micropulse laser (HSML) for treating cCSC, leading to a significantly higher proportion of patients with complete resolution of subretinal fluid (SRF) and functional improvement. Full-Text PDF" @default.
• W4241169774 created "2022-05-12" @default.
• W4241169774 creator A5008174671 @default.
• W4241169774 creator A5031269517 @default.
• W4241169774 creator A5046326117 @default.
• W4241169774 creator A5046758749 @default.
• W4241169774 creator A5048309856 @default.
• W4241169774 creator A5059343622 @default.
• W4241169774 creator A5066789689 @default.
• W4241169774 creator A5071502501 @default.
• W4241169774 creator A5082031977 @default.
• W4241169774 creator A5083258664 @default.
• W4241169774 creator A5085326946 @default.
• W4241169774 creator A5085891882 @default.
• W4241169774 creator A5086662698 @default.
• W4241169774 creator A5086926273 @default.
• W4241169774 date "2019-01-01" @default.
• W4241169774 modified "2023-10-16" @default.
• W4241169774 title "Reply" @default.
• W4241169774 doi "https://doi.org/10.1016/j.ophtha.2018.06.038" @default.
• W4241169774 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30470545" @default.
• W4241169774 hasPublicationYear "2019" @default.
• W4241169774 type Work @default.
• W4241169774 citedByCount "0" @default.
• W4241169774 crossrefType "journal-article" @default.
• W4241169774 hasAuthorship W4241169774A5008174671 @default.
• W4241169774 hasAuthorship W4241169774A5031269517 @default.
• W4241169774 hasAuthorship W4241169774A5046326117 @default.
• W4241169774 hasAuthorship W4241169774A5046758749 @default.
• W4241169774 hasAuthorship W4241169774A5048309856 @default.
• W4241169774 hasAuthorship W4241169774A5059343622 @default.
• W4241169774 hasAuthorship W4241169774A5066789689 @default.
• W4241169774 hasAuthorship W4241169774A5071502501 @default.
• W4241169774 hasAuthorship W4241169774A5082031977 @default.
• W4241169774 hasAuthorship W4241169774A5083258664 @default.
• W4241169774 hasAuthorship W4241169774A5085326946 @default.
• W4241169774 hasAuthorship W4241169774A5085891882 @default.
• W4241169774 hasAuthorship W4241169774A5086662698 @default.
• W4241169774 hasAuthorship W4241169774A5086926273 @default.
• W4241169774 hasBestOaLocation W42411697741 @default.
• W4241169774 hasConcept C118487528 @default.
• W4241169774 hasConcept C126322002 @default.
• W4241169774 hasConcept C141071460 @default.
• W4241169774 hasConcept C150173356 @default.
• W4241169774 hasConcept C168563851 @default.
• W4241169774 hasConcept C178790620 @default.
• W4241169774 hasConcept C185592680 @default.
• W4241169774 hasConcept C203092338 @default.
• W4241169774 hasConcept C2778257484 @default.
• W4241169774 hasConcept C2779100554 @default.
• W4241169774 hasConcept C2781323092 @default.
• W4241169774 hasConcept C71924100 @default.
• W4241169774 hasConceptScore W4241169774C118487528 @default.
• W4241169774 hasConceptScore W4241169774C126322002 @default.
• W4241169774 hasConceptScore W4241169774C141071460 @default.
• W4241169774 hasConceptScore W4241169774C150173356 @default.
• W4241169774 hasConceptScore W4241169774C168563851 @default.
• W4241169774 hasConceptScore W4241169774C178790620 @default.
• W4241169774 hasConceptScore W4241169774C185592680 @default.
• W4241169774 hasConceptScore W4241169774C203092338 @default.
• W4241169774 hasConceptScore W4241169774C2778257484 @default.
• W4241169774 hasConceptScore W4241169774C2779100554 @default.
• W4241169774 hasConceptScore W4241169774C2781323092 @default.
• W4241169774 hasConceptScore W4241169774C71924100 @default.
• W4241169774 hasIssue "1" @default.
• W4241169774 hasLocation W42411697741 @default.
• W4241169774 hasLocation W42411697742 @default.
• W4241169774 hasOpenAccess W4241169774 @default.
• W4241169774 hasPrimaryLocation W42411697741 @default.
• W4241169774 hasRelatedWork W2001002914 @default.
• W4241169774 hasRelatedWork W2030972003 @default.
• W4241169774 hasRelatedWork W2036214396 @default.
• W4241169774 hasRelatedWork W2067364714 @default.
• W4241169774 hasRelatedWork W2082054485 @default.
• W4241169774 hasRelatedWork W2094955902 @default.
• W4241169774 hasRelatedWork W2130134664 @default.
• W4241169774 hasRelatedWork W2342988613 @default.
• W4241169774 hasRelatedWork W2536221331 @default.
• W4241169774 hasRelatedWork W3161569087 @default.
• W4241169774 hasVolume "126" @default.
• W4241169774 isParatext "false" @default.
• W4241169774 isRetracted "false" @default.
• W4241169774 workType "article" @default.